
1. Gut. 2021 Nov 19. pii: gutjnl-2021-326258. doi: 10.1136/gutjnl-2021-326258. [Epub
ahead of print]

HBV antigens quantity: duration and effect on functional cure.

Bertoletti A(1), Boni C(2).

Author information: 
(1)Programme in Emerging Infectious Diseases, Duke-Nus Medical School, Singapore 
antonio@duke-nus.edu.sg.
(2)Laboratory of Viral Immunopathology, Unit of Infectious diseases and
Hepatology, Parma, Italy.

DOI: 10.1136/gutjnl-2021-326258 
PMID: 34799373 

Conflict of interest statement: Competing interests: AB declares the following
relationship with commercial entities developing therapeutics for HBV treatment. 
He acted as a consultant and served on the advisory boards of Assembly
Biosciences, Gilead Sciences, Roche, Jansseen-Cilag, Vir, Molecular Therapies and
HUMABS BioMed. AB is also a co-founder of LION TCR Pte. a biotech company
developing T-cell receptors for treatment of virus-related cancers and chronic
viral diseases.

